Dyne Therapeutics (DYN) Cash from Operations (2019 - 2026)
Dyne Therapeutics (DYN) posted quarterly Cash from Operations of 130286000.0 for Q2 2026, down 37.57% year-over-year from 208702216.81 in Q2 2025, and up 10.1% quarter-over-quarter from 144922000.0 in Q1 2026.
Powered by 
Analysis
Dyne Therapeutics (DYN) Cash from Operations (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Cash from Operations for 8 consecutive years, with 130286000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Operations fell 37.57% year-over-year to 130286000.0; the TTM figure through Jun 2026 stood at 477819000.0 (down 32.89% YoY), while the FY2025 annual figure was 403207000.0, down 37.91% from the prior year.
- Cash from Operations advanced to 130286000.0 in Q2 2026 per DYN's latest filing, from 144922000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 29192000.0 in Q4 2022 and bottomed at 144922000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 72921500.0 across 5 years, with a median of 65135500.0 in 2023.
- On a YoY basis, Cash from Operations climbed as much as 33.02% in 2022 and fell as far as 175.86% in 2022.
- Dyne Therapeutics' Cash from Operations stood at 29192000.0 in 2022, then fell by 19.92% to 35006000.0 in 2023, then tumbled by 140.92% to 84335000.0 in 2024, then plunged by 32.6% to 111832000.0 in 2025, then slipped by 16.5% to 130286000.0 in 2026.
- Business Quant data shows DYN's Cash from Operations at 130286000.0 in Q2 2026, 144922000.0 in Q1 2026, and 111832000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Dyne Therapeutics | 4.02 Bn | 4.02 Bn | - | -130.29 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -130.29 Mn |
| Mar 31, 2026 | -144.92 Mn |
| Dec 31, 2025 | -111.83 Mn |
| Sep 30, 2025 | -90.78 Mn |
| Jun 30, 2025 | -94.70 Mn |
| Mar 31, 2025 | -105.89 Mn |
| Dec 31, 2024 | -84.34 Mn |
| Sep 30, 2024 | -74.63 Mn |
| Jun 30, 2024 | -54.87 Mn |
| Mar 31, 2024 | -78.54 Mn |
| Dec 31, 2023 | -35.01 Mn |
| Sep 30, 2023 | -50.60 Mn |
| Jun 30, 2023 | -55.64 Mn |
| Mar 31, 2023 | -46.91 Mn |
| Dec 31, 2022 | -29.19 Mn |
| Sep 30, 2022 | -42.81 Mn |
| Jun 30, 2022 | -30.91 Mn |
| Mar 31, 2022 | -50.74 Mn |
| Dec 31, 2021 | -28.07 Mn |
| Sep 30, 2021 | -26.95 Mn |